Extending the Span of Time in nAMD and DME Management

Overview

Provider Statement

This continuing education activity is provided by

Support Statement

This activity is supported by an educational grant from Genentech, a member of the Roche Group.

Activity Description

Intravitreal anti-vascular endothelial growth factor (VEGF) therapies have significantly enhanced visual and anatomical outcomes for patients with diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD). However, real-world outcomes are not always comparable to those demonstrated in pinnacle clinical studies, in part due to treatment burden and lack of patient adherence. Corticosteroids are another effective therapeutic option for those patients with DME, but these agents are often not effectively integrated into clinical management protocols. The continued refinement of treatment protocols with FDA-approved therapies and the integration of novel delivery systems and agents with unique mechanisms of action into practice are means of addressing the treatment burden through extending the interval between dosing schedules while maintaining initial visual acuity gains. In this continuing medical education activity, experts in the field assess new injectable-based protocols that lessen the treatment burden as well as evaluate new surgical interventions and procedures that can optimize the treatment of patients with nAMD and DME.

Target Audience

The intended audience for this activity is ophthalmologists and other health care professionals involved in the management of patients with neovascular age-related macular degeneration (nAMD) and/or diabetic macular edema (DME).

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

• Assess new injectable-based protocols that lessen the treatment burden of patients with nAMD and DME.
• Describe new surgical interventions and procedures that can optimize the treatment of patients with nAMD and DME.

Activity Chair

Rishi P. Singh, MD
Staff Physician and President
Cleveland Clinic Martin Hospitals
Stuart, FL
Professor of Ophthalmology, Lerner College of Medicine
Case Western Reserve University
Cleveland, OH

Faculty

John W. Kitchens, MD
Vitreoretinal Surgeon
Retina Associates of Kentucky
Lexington, KY

Reviewer

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP

Accreditation

In support of improving patient care, Vindico Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, January 20, 2023, to January 19, 2024.

How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 2 of the 3 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.

Disclosures

Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Activity Chair and Faculty report the following relevant financial relationship(s)

John W. Kitchens, MD
Consultant: Alcon, Alimera, Allergan, Apellis, Bayer, Genentech, Optos, Regeneron, Roche, Zeiss
Speaker Contracted by Ineligible Company: Alcon, Bayer, Genentech, Regeneron, Roche
Individual Stocks and Stock Options: Kodiak, Outlook

Rishi P. Singh, MD
Consultant: Alcon, Apellis, AsclepiX, Bausch + Lomb, Genentech, Gyroscope, Iveric Bio, Novartis, Regeneron

Reviewer reports the following relevant financial relationship(s)

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Vindico Medical Education staff report the following relevant financial relationship(s)

No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. © 2023 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at cme@vindicoCME.com